Sandoz deal with Pear on digital therapeutics for SUD & OUD

Swiss pharma giant Novartis’ (NOVN: VX) generics and biosimilar division Sandoz has entered into a collaboration with USA-based Pear Therapeutics to commercialize and continued development of novel prescription digital therapeutics designed to effectively treat disease and improve clinical outcomes for patients.

The collaboration brings together Sandoz expertise in launching and commercializing treatments with Pear's leading experience in digital therapeutics design and implementation.

Sandoz and Pear will work together to bring reSET to patients with substance use disorder (SUD) and, if cleared by the US Food and Drug Administration, reSET to patients with opioid use disorder (OUD) who are currently receiving buprenorphine, to better address the full burden of their illnesses. Pear’s flagship digital therapeutic, reSET, was cleared by the FDA in September 2017 to help treat Substance Use Disorder.